Evaluation of the Efficacy of Calcium a -Ketoglutarate(AKG-Ca) in Improving Human Aging
Key claim: A randomized, double-blind, placebo-controlled trial will test whether 12 weeks of calcium alpha-ketoglutarate (CaAKG) improves biological age (PhenoAge) and related health markers in generally healthy adults aged 45–75.
Abstract
This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effects of calcium alpha-ketoglutarate (CaAKG) supplementation on biological aging and age-related health indicators in middle-aged and older adults. Alpha-ketoglutarate (AKG), a key intermediate in the Krebs cycle, has been investigated for its potential role in modulating aging-related metabolic and cellular pathways. Due to the poor oral bioavailability of free AKG, its stabilized form-calcium alpha-ketoglutarate (CaAKG)-is used to enhance absorption and additionally provides calcium supplementation benefits. At the population level, there is currently a lack of systematic assessment studies on the effects of CaAKG on human ageing-related indicators.
The study will recruit generally healthy adults aged 45 to 75 years. Participants will be randomly assigned to receive either CaAKG or a placebo daily for 12 weeks. The primary objective is to assess changes in biological aging, as measured by PhenoAge. Secondary outcomes include changes in physical performance, inflammatory markers, glucose and lipid metabolism, ageing-related gene expression, and self-reported quality of life.
This trial is designed to provide evidence on the efficacy and safety of CaAKG as a potential dietary intervention to support healthy aging. All participants will undergo pre- and post-intervention assessments. The study has been reviewed and approved by Medical Ethics Committee of Zhejiang Chinese Medical University, and informed consent will be obtained from all participants prior to enrollment.
Why this matters
CaAKG has been popular in the longevity supplement scene largely on the back of a single retrospective TruAge report and mouse healthspan data, so a prospective double-blind RCT with PhenoAge as the pre-specified primary endpoint is the kind of test that could either anchor or deflate the current enthusiasm. Until readout, the compound’s evidence base remains animal-model and anecdotal-biohack — the protocol matters as a pathway, not as proof.